mAb 4A8

A human monoclonal antibody against SARS-CoV-2 Spike protein.

Phase of research

Potential treatment - pre-clinical evidence

How it helps


Drug status


Supporting references
Contradictory references
AI-suggested references
Clinical trials

General information

mAb 4A8 is a human monoclonal antibody against SARS-CoV-2 Spike protein identified among the antibodies produced in convalescent patients' B cells. It neutralizes SARS-CoV-2 (live or pseudotyped virus) despite not interfering with Spike-ACE2 interaction (Chi et al., 2020). mAB 4A8 targets a SARS-CoV-2 Spike N-terminal domain glycan-free site (Cerutti et al., 2021).


Supporting references

Link Tested on Impact factor Notes Publication date
A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
Spike protein In vitro Antibody
in vitro binding assay; Vero E6 cells; ACE2-293T cells; hACE2-(HEK)293T cells (S-ACE2 interaction assay) 41.85

Potently neutralized live SARS-CoV-2 and S-protein pseudotyped SARS-CoV-2 in vitro (EC50 of 0.61 μg/ml and 49 μg/ml, respectively). The antibody bound S1 domain of Spike protein with Kd of 92.7 nM. Despite its potent neutralizing activity, it did not inhibit the interaction between Spike protein and host's ACE2 receptor.

Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite
Spike protein Cryo-EM Crystallization Biophysical assay In vitro Antibody
in vitro biophysical assay; crystallization; cryo-EM; Vero E6; (VSV) SARS-CoV-2 Spike-pseudotyped virus; SARS-CoV-2 live virus 15.92

Targets a SARS-CoV-2 Spike protein N-terminal domain supersite. The site is glycan-free and electropositive and is recognized by multiple neutralizing antibodies (the epitopes are overlapping but the recognition might differ).